JP2025510912A - 双極性障害を処置するための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン - Google Patents

双極性障害を処置するための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン Download PDF

Info

Publication number
JP2025510912A
JP2025510912A JP2024557191A JP2024557191A JP2025510912A JP 2025510912 A JP2025510912 A JP 2025510912A JP 2024557191 A JP2024557191 A JP 2024557191A JP 2024557191 A JP2024557191 A JP 2024557191A JP 2025510912 A JP2025510912 A JP 2025510912A
Authority
JP
Japan
Prior art keywords
dmt
meo
pharma
acceptable salt
score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024557191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510912A5 (enExample
Inventor
タイス・ターヴィ
コナー・バーク
ナオイス・ガフニー
Original Assignee
ジーエイチ・リサーチ・アイルランド・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジーエイチ・リサーチ・アイルランド・リミテッド filed Critical ジーエイチ・リサーチ・アイルランド・リミテッド
Publication of JP2025510912A publication Critical patent/JP2025510912A/ja
Publication of JP2025510912A5 publication Critical patent/JP2025510912A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024557191A 2022-03-27 2023-03-27 双極性障害を処置するための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン Pending JP2025510912A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP22000083.0 2022-03-27
EP22000086 2022-03-27
EP22000086.3 2022-03-27
EP22000083 2022-03-27
EP23153995.8 2023-01-30
EP23153939 2023-01-30
EP23153995 2023-01-30
EP23153939.6 2023-01-30
PCT/EP2023/057842 WO2023186806A1 (en) 2022-03-27 2023-03-27 5-methoxy-n,n-dimethyltryptamine for the treatment of bipolar disorder

Publications (2)

Publication Number Publication Date
JP2025510912A true JP2025510912A (ja) 2025-04-15
JP2025510912A5 JP2025510912A5 (enExample) 2026-04-10

Family

ID=86007166

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2024557191A Pending JP2025510912A (ja) 2022-03-27 2023-03-27 双極性障害を処置するための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン
JP2024557759A Pending JP2025510369A (ja) 2022-03-27 2023-03-27 社会的／情動的引きこもりまたは離隔の処置のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン
JP2024557755A Pending JP2025511081A (ja) 2022-03-27 2023-03-27 睡眠障害の治療における使用のための５－ＭｅＯ－ＤＭＴ
JP2024557758A Pending JP2025510368A (ja) 2022-03-27 2023-03-27 不安の処置
JP2024557205A Pending JP2025510916A (ja) 2022-03-27 2023-03-27 精神運動遅滞の治療のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン
JP2024557204A Pending JP2025512831A (ja) 2022-03-27 2023-03-27 認知機能障害の治療

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2024557759A Pending JP2025510369A (ja) 2022-03-27 2023-03-27 社会的／情動的引きこもりまたは離隔の処置のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン
JP2024557755A Pending JP2025511081A (ja) 2022-03-27 2023-03-27 睡眠障害の治療における使用のための５－ＭｅＯ－ＤＭＴ
JP2024557758A Pending JP2025510368A (ja) 2022-03-27 2023-03-27 不安の処置
JP2024557205A Pending JP2025510916A (ja) 2022-03-27 2023-03-27 精神運動遅滞の治療のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン
JP2024557204A Pending JP2025512831A (ja) 2022-03-27 2023-03-27 認知機能障害の治療

Country Status (9)

Country Link
US (9) US20250241893A1 (enExample)
EP (7) EP4499088A1 (enExample)
JP (6) JP2025510912A (enExample)
KR (6) KR20250005183A (enExample)
CN (2) CN119095595A (enExample)
AU (6) AU2023246774A1 (enExample)
CA (6) CA3255348A1 (enExample)
IL (6) IL315899A (enExample)
WO (9) WO2023186820A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3753923A1 (en) 2019-06-19 2020-12-23 GH Research Limited Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent
EP4155306A1 (en) 2021-01-15 2023-03-29 Beckley Psytech Limited Neuroactive ergoline analogue
US12534441B2 (en) 2021-01-15 2026-01-27 Beckley Psytech Limited Tryptamine analogues
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
GB202306256D0 (en) * 2023-04-27 2023-06-14 Beckley Psytech Ltd 5-Methoxy-N,N-Dimethyltryptamine Formulations
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
WO2026078143A1 (en) 2024-10-09 2026-04-16 GH Research Ireland Limited Combinations of 5-meo-dmt with antidepressants for treating depression

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19803376C1 (de) 1998-01-29 1999-10-14 Markus Storz Inhalator zur Erzeugung von aroma- und/oder wirkstoffhaltigen Dämpfen aus Pflanzenmaterial und/oder Flüssigkeiten
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US20040234916A1 (en) 2003-05-21 2004-11-25 Alexza Molecular Delivery Corporation Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same
ES2355983T3 (es) 2006-08-01 2011-04-01 STOBI GMBH & CO. KG Balón de válvula para inhaladores .
MA50786A (fr) * 2017-10-26 2022-04-27 Blumentech S L Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
FI4349407T3 (fi) 2019-02-22 2025-06-02 Gh Res Ireland Limited 5-metoksi-n,n-dimetyylitryptamiini (5-meo-dmt) vaikean masennuksen hoitoon
HUE069534T2 (hu) * 2019-02-22 2025-03-28 Gh Res Ireland Limited 5-Metoxi-N,N-dimetiltriptamint (5-MeO-DMT) tartalmazó készítmény mentális rendellenességek kezelésében történõ alkalmazásra
US12377112B2 (en) * 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
EP3868364A1 (en) * 2020-02-24 2021-08-25 GH Research Limited Aerosol comprising 5-methoxy-n,n-dimethyltryptamine
WO2021216489A1 (en) * 2020-04-20 2021-10-28 Lobe Sciences Ltd. Methods for treating mild traumatic brain injury, post traumatic stress disorder and mild traumatic brain injury
BR112022025306A2 (pt) * 2020-06-12 2023-02-28 Beckley Psytech Ltd Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina
US11406619B2 (en) * 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
US20240299353A1 (en) 2021-03-12 2024-09-12 Alvarius Pharmaceuticals Ltd. Compositions and methods for treating addictions comprising 5-meo-dmt

Also Published As

Publication number Publication date
IL315897A (en) 2024-11-01
US20250205256A1 (en) 2025-06-26
CN119053327A (zh) 2024-11-29
KR20250005183A (ko) 2025-01-09
IL315898A (en) 2024-11-01
WO2023186823A1 (en) 2023-10-05
WO2023186835A1 (en) 2023-10-05
CA3255343A1 (en) 2023-10-05
KR20240167879A (ko) 2024-11-28
CA3255629A1 (en) 2023-10-05
WO2023186826A1 (en) 2023-10-05
IL315899A (en) 2024-11-01
WO2023186820A1 (en) 2023-10-05
CA3255340A1 (en) 2023-10-05
US20250241892A1 (en) 2025-07-31
US20250241893A1 (en) 2025-07-31
WO2023186829A1 (en) 2023-10-05
AU2023242291A1 (en) 2024-11-07
EP4499083A1 (en) 2025-02-05
EP4499088A1 (en) 2025-02-05
EP4499076A1 (en) 2025-02-05
AU2023246545A1 (en) 2024-11-07
EP4499082A1 (en) 2025-02-05
IL315896A (en) 2024-11-01
US20250213532A1 (en) 2025-07-03
AU2023246679A1 (en) 2024-11-07
EP4499075A1 (en) 2025-02-05
CN119095595A (zh) 2024-12-06
AU2023246543A1 (en) 2024-11-07
AU2023244452A1 (en) 2024-11-07
CA3255348A1 (en) 2023-10-05
CA3255505A1 (en) 2023-10-05
US20250241895A1 (en) 2025-07-31
JP2025510916A (ja) 2025-04-15
US20250241891A1 (en) 2025-07-31
JP2025512831A (ja) 2025-04-22
CA3255648A1 (en) 2023-10-05
WO2023186797A1 (en) 2023-10-05
KR20250005176A (ko) 2025-01-09
JP2025510369A (ja) 2025-04-14
IL315902A (en) 2024-11-01
EP4499073A1 (en) 2025-02-05
WO2023186806A1 (en) 2023-10-05
US20250205199A1 (en) 2025-06-26
KR20250005181A (ko) 2025-01-09
US20240108601A1 (en) 2024-04-04
IL315891A (en) 2024-11-01
JP2025510368A (ja) 2025-04-14
WO2023186830A1 (en) 2023-10-05
JP2025511081A (ja) 2025-04-15
US20240108602A1 (en) 2024-04-04
KR20250005170A (ko) 2025-01-09
WO2023186816A1 (en) 2023-10-05
KR20250005179A (ko) 2025-01-09
EP4499226A1 (en) 2025-02-05
AU2023246774A1 (en) 2024-11-07

Similar Documents

Publication Publication Date Title
JP2025510912A (ja) 双極性障害を処置するための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン
JP2025510913A (ja) 双極性障害の処置のための５－ＭｅＯ－ＤＭＴ
KR20250139377A (ko) 수유부의 정신 장애 치료에 사용하기 위한 5-메톡시-n,n-다이메틸트립타민
JP2026505778A (ja) 産後うつ病の処置における５－ｍｅｏ－ｄｍｔの使用
TW200821296A (en) Use of sertindole for the preventive treatment of suicidal behaviour
CN118973569A (zh) 用于治疗双相情感障碍的5-甲氧基-n,n-二甲基色胺
JP2025511072A (ja) 産後うつ病の処置に使用するための５－ＭｅＯ－ＤＭＴ
JP2025510915A (ja) 産後うつ病の処置のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン
JP2025510911A (ja) 精神障害の治療

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260327